Hydrophilic/lipophilic polymeric matrix dosage formulation

Details Hydrophilic/lipophilic polymeric matrix dosage formulation Hydrophilic/lipophilic polymeric matrix dosage formulation

2011-04-19

2011-04-19

Oh, Taylor Victor (Department: 1625)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S468000, C424S472000, C514S418000

Reexamination Certificate

active

07927624

ABSTRACT:
An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.

REFERENCES:
patent: 3065143 (1962-11-01), Christenson et al.
patent: 4160020 (1979-07-01), Ayer et al.
patent: 4369172 (1983-01-01), Schor et al.
patent: 4389393 (1983-06-01), Schor et al.
patent: 4756911 (1988-07-01), Drost et al.
patent: 4824860 (1989-04-01), Owen
patent: 4839177 (1989-06-01), Colombo et al.
patent: 4865849 (1989-09-01), Conte et al.
patent: 4946685 (1990-08-01), Edgren et al.
patent: 5126145 (1992-06-01), Evenstad et al.
patent: 5213808 (1993-05-01), Bar-Shalom et al.
patent: 5326570 (1994-07-01), Rudnic et al.
patent: 5395626 (1995-03-01), Kotwal et al.
patent: 5407686 (1995-04-01), Patel et al.
patent: 5422121 (1995-06-01), Lehmann et al.
patent: 5422123 (1995-06-01), Conte et al.
patent: 5487901 (1996-01-01), Conte et al.
patent: 5496836 (1996-03-01), Di Rocco et al.
patent: 5510114 (1996-04-01), Borella et al.
patent: 5620705 (1997-04-01), Dong et al.
patent: 5626874 (1997-05-01), Conte et al.
patent: 5645858 (1997-07-01), Kotwal et al.
patent: 5650169 (1997-07-01), Conte et al.
patent: 5738874 (1998-04-01), Conte et al.
patent: 5780057 (1998-07-01), Conte et al.
patent: 5807570 (1998-09-01), Chen et al.
patent: 5955104 (1999-09-01), Momberger et al.
patent: 6027748 (2000-02-01), Conte et al.
patent: 6149940 (2000-11-01), Maggi et al.
patent: 6183779 (2001-02-01), Ouali et al.
patent: 6217905 (2001-04-01), Edgren et al.
patent: 6218421 (2001-04-01), King
patent: 6531151 (2003-03-01), Besse
patent: 2010/0003320 (2010-01-01), Vergnault et al.
patent: 0 113 964 (1984-07-01), None
patent: 0 133 964 (1984-07-01), None
patent: 0 226 884 (1987-07-01), None
patent: 0 299 602 (1989-01-01), None
patent: 0 300 614 (1989-01-01), None
patent: 0 384 514 (1990-08-01), None
patent: 0 432 607 (1991-06-01), None
patent: 0 432 607 (1991-06-01), None
patent: 0 527 835 (1994-10-01), None
patent: 0 624 373 (1994-11-01), None
patent: 0 656 204 (1995-06-01), None
patent: 0 663 820 (1995-07-01), None
patent: 0 788 790 (1997-08-01), None
patent: 0 795 324 (1997-09-01), None
patent: 4-360826 (1992-12-01), None
patent: 2772695 (1998-04-01), None
patent: WO 91/16306 (1991-10-01), None
patent: WO 92/00735 (1992-01-01), None
patent: WO 93/23035 (1993-11-01), None
patent: WO 94/06416 (1994-03-01), None
patent: WO-9639136 (1996-12-01), None
patent: WO 97/03670 (1997-02-01), None
patent: WO-9703670 (1997-02-01), None
patent: WO 97/48385 (1997-12-01), None
patent: WO 98/00115 (1998-01-01), None
patent: WO 98/30208 (1998-07-01), None
patent: WO-9949852 (1999-10-01), None
patent: WO 99/62496 (1999-12-01), None
patent: WO 02/11702 (2002-02-01), None
Dimitriu, S., “Polysaccharides in Medical Applications”, Marcel Dekker, Inc., pp. 730-754 (1996).
DrugBank, “Theophylline”, Acc. No. DB00277, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=%20DB00277, pp. 1-30, Jun. 13, 2005.
DrugBank, “Ursodeoxycholic acid”, Acc. No. DB01586, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=%20DB01586, pp. 1-8, Aug. 29, 2007.
DrugBank, “Prednisolone”, Acc. No. DB00860, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=%20DB00860, pp. 1-13, Jun. 13, 2005.
DrugBank, “Carbamazepine”, Acc. No. DB00564, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=%20DB00564, pp. 1-14, Jun. 13, 2005.
DrugBank, “Diclofenac”, Acc. No. DB00586, http://www.drugbank.ca/cgi-bin/getCard.cai?CARD=%20DB00527, pp. 1-19, Jun. 13, 2005.
DrugBank, “Omeprazole”, Acc. No. DB00338, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=%20DB00338, pp. 1-11, Jun. 13, 2005.
Gennaro et al., in Remington's Pharmaceutical Sciences, 18thEd., Mack Publishing Company, Easton, PA, Ch. 19, p. 304 (1990).
GlaxoSmithKline, “PAXIL®”, http://us.gsk.com/products/assets/us—paxil.pdf, pp. 1-43, Jun. 2008.
Griffin, W.C., “Classification of Surface-Active Agents by ‘HLB’”,J. Soc. Cosmetic Chem., 1:311-326 (1949).
Handbook of Pharmaceutical Excipients, 3rdEd., Kibbe, Ed., American Pharmaceutical Assoc., pp. 86-91, 94-95, 142-145, 146-153, 228-229, 252-255, 276-285, 304-309, 316-319, 324-329, 392-399, 416-419, 432-439, 486-489, 500-585 (1986).
“Hydroxypropyl Methylcellulose”,U.S. Pharmacopeia, The National Formulary, U.S. Pharmacopeial Convention, National Publishing Philadelphia, pp. 843-844 (1999).
Dumitriu, S., “Polysaccharides in Medical Applications”, Marcel Dekker, Inc., pp. 730-754 (1996).
DrugBank: showing Theophylline, Primary Accession No. DB00277 http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=DB00277, pp. 1-28, Jun. 13, 2005.
DrugBank: showing Ursodeoxycholic acid, Primary Accession No. DB01586, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=DB01586, pp. 1-7, Aug. 29, 2007.
DrugBank: showing Prednisolone, Primary Accession No. DB00860, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=DB00860, pp. 1-12, Jun. 13, 2005.
DrugBank: showing Carbamazepine, Primary Accession No. DB00564, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=DB00564, pp. 1-12, Jun. 13, 2005.
DrugBank: showing Diclofenac, Primary Accession No. DB00586, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=DB00527, pp. 1-16, Jun. 13, 2005.
DrugBank: showing Omeprazole, Primary Accession No. DB00338, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=DB00338, pp. 1-10, Jun. 13, 2005.
DrugBank: showing Diclofenac (DB00586, Primary Accession No. DB00586, http://www.drugbank.ca/cgi-bin/getCard.cgi?CARD=DB00586, pp. 1-16 (2005).
Conte , U. and Maggi, L., “Multi-layer tablets as drug delivery devices”,Pharmaceutical Technology Europe, pp. 18, 20, 22 24 and 25, Feb. 1998.
Opposition filed by Maiwald on Apr. 21, 2009, and received at the EPO on Apr. 21, 2009, via facsimile, Re Application No. 01 921 605.0, (EP Patent 1 272 167), 16 pages.
Analytical Profiles of Drug Substances, Ed. Klans Florey, Academic Press Inc., 18:228-229 (1989).
Ballard, Berton E., “Prolonged-Action Pharmaceuticals”,Remington's Pharmaceutical Sciences, Chapter91.
Boles et al., “Design and evaluation of a sustained release aminophylline tablet”,Drug Development and Industrial Pharmacy, 19(3):340-370 (1993).
Lordi, Nicholas J., “Sustained Release Dosage Forms”,The Theory and Practice of IndustrialPharmacy, 3rded., eds. Lachman, Lieberman and Kanig, Lea & Febiger, Chapter 14, 2009.
Martindale: The Complete Drug Reference—Monographs, The Pharmaceutical Press, pages relating to nifedipine and ketoprofen, 2000.
Study 166, phase II clinical trial, which ran from Nov. 1, 2000 to Oct. 3, 2001, available on http://ctr.gsk.ci/uk/summary/ropinirole/strudylist.asp.
Web page from “Drug Bank” at http://redpoll.pharmacy.ualberta.ca/drugbank, 2007.
“Ropinirole prolonged release: a guide to its use in Parkinson's disease”,Drugs and Therapy Perspectives, 25(6):1-5 (2009).
Edin et al., “Adherence among patients with Parkinson's disease taking ropinirole immediate release at least three times daily”, 12th International Congress of Parkinson's disease and Movement Disorders, Chicago, IL, USA (Jun. 22-26, 2008).
Kaye and Nicholls, “Clinical Pharmacokinetics of Ropinirole”,Clin. Pharmacokinet., 39(4):243-254 (2000).
Kulkarni et al., “Medication Adherence and Associated Outcomes in Medicare Health Maintenance Organization-Enrolled Older Adults with Parkinson's Disease”,Mov. Dis., 23:359-365-365 (2008).
Lee and Kim, “Probing the mechanisms of drug release from hydrogels”,J. Controlled Release, 16:229-236 (1991).
Longer and Robinson, “Sustained-Release Drug Delivery Systems”, inRemington's Pharmaceutical Sciences, 18th Ed, Ch.

Affiliated with

Also associated with

Rating

Hydrophilic/lipophilic polymeric matrix dosage formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydrophilic/lipophilic polymeric matrix dosage formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrophilic/lipophilic polymeric matrix dosage formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2645915